• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Penumbra Inc.

    5/15/25 4:03:13 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care
    Get the next $PEN alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001704713
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    PENUMBRA, INC.
    SEC File Number
    001-37557
    Address of Issuer
    One Penumbra Place
    Alameda
    CALIFORNIA
    94502
    Phone
    (510) 748-3200
    Name of Person for Whose Account the Securities are To Be Sold
    BRIDGET A O'ROURKE
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    10028615.003872594005/15/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/30/2024Restricted StockISSUERCheckbox not checked6606/30/2024Not Applicable
    Common03/31/2024Restricted StockISSUERCheckbox not checked3403/31/2024Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    BRIDGET A OROURKE
    One Penumbra Place
    Alameda � CA � 94502
    Common04/15/20255013560.50
    BRIDGET A OROURKE
    One Penumbra Place
    Alameda � CA � 94502
    Common03/03/20255014274.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/15/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/11/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Bridget Anne O'Rourke

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $PEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PEN

    DatePrice TargetRatingAnalyst
    10/8/2025$326.00Hold → Buy
    Needham
    9/2/2025$300.00Outperform
    Evercore ISI
    3/14/2025$320.00Buy
    BofA Securities
    1/21/2025$305.00Buy
    UBS
    12/17/2024$275.00Outperform
    Oppenheimer
    12/11/2024$190.00 → $275.00Equal Weight → Overweight
    Wells Fargo
    9/18/2024$238.00Buy
    Stifel
    9/3/2024$263.00Outperform
    Leerink Partners
    More analyst ratings

    $PEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Gen. Counsel & Secretary Roberts Johanna sold $160,189 worth of shares (600 units at $266.98), decreasing direct ownership by 0.93% to 63,657 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    11/12/25 7:32:29 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Director Grewal Harpreet sold $42,330 worth of shares (186 units at $227.58), decreasing direct ownership by 2% to 8,516 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    11/6/25 7:31:50 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    President Narayan Shruthi covered exercise/tax liability with 1,294 shares, decreasing direct ownership by 5% to 26,961 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    10/17/25 7:32:52 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Penumbra, Inc. Reports Third Quarter 2025 Financial Results

    ALAMEDA, Calif., Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025. Revenue of $354.7 million in the third quarter of 2025, an increase of 17.8% or 16.9% in constant currency1, compared to the third quarter of 2024.Total U.S. revenue of $275.0 million in the third quarter of 2025, an increase of 21.5% compared to the third quarter of 2024.U.S. Thrombectomy revenue of $192.0 million in the third quarter of 2025, an increase of 18.5% compared to the thi

    11/5/25 4:05:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism

    The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulationResults of STORM-PE demonstrating superior efficacy of CAVT with anticoagulation versus anticoagulation alone were also published in Circulation todayALAMEDA, Calif., Nov. 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) announced additional results of the ground-breaking STORM-PE randomized controlled trial (RCT), which found that the use of computer assisted vacuum thrombectom

    11/3/25 3:00:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism

    ALAMEDA, Calif., Oct. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy (CAVT™), with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-high risk pulmonary embolism (PE). The data was presented at a late-breaking session during Transcatheter Cardiovascular Therapeutics® (TCT®), the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®).

    10/27/25 9:00:00 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    SEC Filings

    View All

    SEC Form 10-Q filed by Penumbra Inc.

    10-Q - Penumbra Inc (0001321732) (Filer)

    11/5/25 4:44:08 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Penumbra Inc (0001321732) (Filer)

    11/5/25 4:15:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Penumbra Inc (0001321732) (Filer)

    8/27/25 9:05:02 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Leadership Updates

    Live Leadership Updates

    View All

    New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile

    Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif., Sept. 9, 2025 /PRNewswire/ -- The American Venous Forum (AVF), International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra (NYSE:PEN), The PERT Consortium® and Society for Vascular Medicine (SVM), which have come together to form the Get Out the Clot campaign, today announced findings from a new survey assessing the current state of venous thromboembolism (VTE) care, also known as blood clots in the body. Get Out the Clot is a collaborative educational initiative to help identify gaps in patient

    9/9/25 9:00:00 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

    Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i

    10/10/24 9:00:00 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors

    SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma

    10/24/22 8:30:00 AM ET
    $BLZE
    $GSIT
    $PEN
    Computer Software: Prepackaged Software
    Technology
    Semiconductors
    Medical/Dental Instruments

    $PEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Penumbra upgraded by Needham with a new price target

    Needham upgraded Penumbra from Hold to Buy and set a new price target of $326.00

    10/8/25 8:21:11 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on Penumbra with a new price target

    Evercore ISI initiated coverage of Penumbra with a rating of Outperform and set a new price target of $300.00

    9/2/25 8:39:14 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    BofA Securities initiated coverage on Penumbra with a new price target

    BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00

    3/14/25 7:46:38 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

    SC 13G/A - Penumbra Inc (0001321732) (Subject)

    11/14/24 1:22:36 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

    SC 13G/A - Penumbra Inc (0001321732) (Subject)

    11/12/24 12:53:28 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Penumbra Inc.

    SC 13G - Penumbra Inc (0001321732) (Subject)

    2/14/24 10:03:02 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Financials

    Live finance-specific insights

    View All

    Penumbra, Inc. Reports Third Quarter 2025 Financial Results

    ALAMEDA, Calif., Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025. Revenue of $354.7 million in the third quarter of 2025, an increase of 17.8% or 16.9% in constant currency1, compared to the third quarter of 2024.Total U.S. revenue of $275.0 million in the third quarter of 2025, an increase of 21.5% compared to the third quarter of 2024.U.S. Thrombectomy revenue of $192.0 million in the third quarter of 2025, an increase of 18.5% compared to the thi

    11/5/25 4:05:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025

    ALAMEDA, Calif., Oct. 8, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM Eastern Time at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) Conference. Management and members of the STORM-PE steering committee will discuss the Company's STORM-PE clinical trial followed by a question-and-answer session. A live webcast of the event can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion o

    10/8/25 4:30:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra, Inc. Reports Second Quarter 2025 Financial Results

    ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency1, compared to the second quarter of 2024.U.S. Thrombectomy revenue of $188.5 million in the second quarter of 2025, an increase of 22.6% compared to the second quarter of 2024. U.S. VTE revenue increased 42% compared to the same period a year ago.Income from operations of $40.8 mil

    7/29/25 4:05:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care